PPAR Alpha Agonist Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2024

Peroxisome proliferator-activated receptor alpha (PPAR-α), also known as NR1C1 (nuclear receptor subfamily 1, group C, member 1), is a nuclear receptor protein functioning as a transcription factor that in humans is encoded by the PPARA gene. PPAR-α is a transcription factor regulated by free fatty acids, and is a major regulator of lipid metabolism in the liver. PPAR-alpha is activated under conditions of energy deprivation and is necessary for the process of ketogenesis, a key adaptive response to prolonged fasting. Mechanism of action (MOA) of PPAR Alpha Agonist forms a heterodimeric complex with another nuclear receptor called retinoid X receptor (RXR). This complex is then translocated into the nucleus and in the nucleus, the PPAR-alpha/RXR complex binds to specific DNA sequences called PPREs in the promoter regions of target genes. PPREs are typically located upstream of genes involved in lipid metabolism, such as those related to fatty acid oxidation, lipid transport, and inflammation. PPAR Alpha Agonist is used in the treatment of endocrine system diseases, diabetes mellitus, glucose metabolism disorder, acute coronary syndrome, digestive system diseases, hyperinsulinism, heart diseases, hypertension, liver diseases, blood coagulation disorder, brain diseases, etc. The rising prevalence of endocrine diseases, diabetes mellitus, and an aging population are the key drivers for PPAR Alpha Agonist market. For instance, according to the World Health Organization 2023, About 422 million people worldwide have diabetes. Moreover, the development of novel molecules by market players is coming up to overcome challenges in therapy. For instance, Roche’s Aleglitazar (R1439) for the treatment of diabetes mellitus is under the various stages of clinical studies.

Key Market Developments:

• In September 2022, according to the Taylor and Francis Journal research findings, modified fenofibrate pellets developed showed enhanced bioavailability and delayed-release properties.

Drugs under the Pipeline for PPAR Alpha Agonist:

• Duvie (Lobeglitazone)
• Aleglitazar (R1439)
• Elafibranor (GFT505)
• Parmodia (Pemafibrate)
• Lipaglyn (Saroglitazar)
• Cholib (Fenofibrate
• Gemcabene (CI-1027)
• Bilessglu (Chiglitazar)
• Lanifibranor (IVA337)
• ABTL0812
• Atorvastatin/Fenofibrate (CKD-337)
• Indeglitazar (PLX204)
• Pemafibrate ER (K-877-ER)
• Cetaxin (Ciprofibrat)
• Ciprol (Ciprofibrate)
• Triglide (Fenofibrate)
• Micro-Palmitoylethanolamide (FSD 201)
• Livasupril (Micronized Fenofibrate/Pitavastatin)
• OMT-28
• Fenocid (Fenofibric Acid)
• Pemafibrate
• DSP-8658
• PLX 200
• SYO 0805
• ZYH7
  
  

Clinical Activity and Developments of PPAR Alpha Agonist:

Till July 2023, more than 25 companies have approximately 31 molecules targeting the many endocrine disorders and diabetes mellitus. For these molecules, more than 78 clinical trials are being conducted and the majority are in phase-2 and phase-3 clinical trials by the players across the globe. For instance,

• In November 2021, Roche has completed the phase 2, randomized, double-blind, study to evaluate the effect of Aleglitazar (R1439) on glycemic control in patients with type 2 diabetes mellitus.
• In May 2023, Ipsen completed phase 1, single-center, open-label, repeat-dose study to evaluate the pharmacokinetics, safety, and tolerability of Elafibranor (GFT505) in healthy Japanese and non-Asian participants.